Immune checkpoint blocking antibodies, including anti-CTLA-4 and anti-PD-1, can induce tumor responses in a variety of tumor types, including melanoma, non-small-cell lung cancer (NSCLC), and kidney renal clear cell carcinoma (KIRC) [60]. This evidence concerns the gene CTLA4 and melanoma.